Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: Bioprinting is the process of creating 3D tissue analogues. For this purpose, it is necessary to produce a special bioink that will be able to recreate the natural environment for cells.Despite the progress in the process of creating biomaterial composites,no equivalent has been obtained for the complexity of the natural ECM,imitating the organ environment. Besides problems with phisico-chemical properties of bioinks for bioprinting, two major challenges are biocompatibility which influence a function of bioprinted tissue and residual detergent analyses which might be crucial in case of FDA and EMA approval for clinical use.The aim of this study was to produce detergent-free dECM-derived bioinks with biocompatibility ready for clinical use.
*Methods: The material to the decellularization was the pancreas and aorta from pigs. The procedure with the TritonX-100 detergent was used. We used standard protocol (group St) and modified with extended rising out of detergent with modified rising solution and modified temperature control(group dt-free).The bioink production protocol consists of 3 stages:(1)dissolution of dECM in a solution of with pepsin,(2)formation of dECM paste,(3)addition of cross-linking agents. Obtained bioinks were analyzed using: viscosity, and fiber morphology assessment. Residual DNA, fat and detergent concentration was assessed. Stability at normothermic conditions as well as cytotoxicity and affinity of cells to the material. Pancreatic petals were printed and in vitro tests of GSIS were analyzed on day 0,1,3 and 7.
*Results: The amount of detergent remaining in the group dt-free was 3.79ug/mg dECM and was significantly lower compared to the St. protocol (p<0.008). The fat content in the dt-free samples was almost 3.5times lower than those to the St group (p<0.001). The proteins structure after decellularization was not affected and the percentage of ECM proteins was the same to the control. Residual DNA for both groups was below acceptable levels. But in the new protocol the amount of DNA was further reduced almost two-fold (p<0.027).GSIS showed islet functionality for 7 days in printed pancreatic petals. Both control islets and those printed in alginate-based bioinks showed a maximum functionality of 24h.
*Conclusions: The obtained results on bioinks have a real chance to be used in future clinical trials.
To cite this abstract in AMA style:Wszola M, Klak M, Tymicki G, Berman A, Kosowska K, Bryniarski T, Cywoniuk P, Gomolka M, Kowalska P, Turowski P, Kaminski A. Production of Detergent-Free ECM-Derived Bioinks for Bioprinting of Bionic Pancreas Ready for Clinical Use [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/production-of-detergent-free-ecm-derived-bioinks-for-bioprinting-of-bionic-pancreas-ready-for-clinical-use/. Accessed April 15, 2021.
« Back to 2020 American Transplant Congress